Strategies and challenges for the next generation of therapeutic antibodies.
Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.
Beck
Alain
A
Centre d'Immunologie Pierre Fabre (CIPF), 5 Avenue Napoléon III, F74160, Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
Wurch
Thierry
T
Bailly
Christian
C
Corvaia
Nathalie
N
D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000737:chemistry; D015202:Protein Engineering
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D016207:Cytokines; D018796:Immunoconjugates; D007074:Immunoglobulin G